SVB Leerink Updates Recursion Pharmaceuticals Rating to Market Perform with Lower Price Target of $8.

Trending News 🌧️

SVB Leerink recently updated their rating on Recursion Pharmaceuticals ($NASDAQ:RXRX) to Market Perform and lowered their price target to $8. Recursion Pharmaceuticals is a biotechnology company that is focused on using artificial intelligence and automated biology to discover new treatments for diseases. The company uses photography of cells from disease models to gather information and develop treatments. Recursion Pharmaceuticals is focused on developing therapies for serious diseases like cancer, rare genetic disorders, and neurological diseases. The company has already identified several drug candidates and is currently working on clinical trials. Recursion Pharmaceuticals has also partnered with pharmaceutical companies to further their research and development efforts.

The company has received positive reviews from investors and analysts, who have praised its innovative approach to drug discovery. They are also concerned about the lack of clinical data available on its drug candidates. Despite the lowered price target, analysts remain optimistic about Recursion Pharmaceuticals’ potential to develop treatments for serious diseases. Investors should carefully consider the risks associated with investing in the company, as well as the potential rewards of its innovative approach to drug discovery.

Price History

At the time of writing, media sentiment towards the stock was generally negative. On Tuesday, RECURSION PHARMACEUTICALS stock opened at $8.6 and closed at $8.6, a decrease of 1.4% from the prior closing price of 8.7. This news comes after the company’s stock has been on a slow decline since the start of the year, and investors are reportedly becoming concerned with the stock’s performance. The lowered price target is likely to have further weighed on the stock’s performance in the near term. Analysts are also cautious about the company’s ability to make money from its drug discovery platform, which is still in its early stages of development. Despite this, analysts remain optimistic about the long-term prospects for Recursion Pharmaceuticals. The company has a strong research and development program, and its drug discovery platform has already been used to develop several novel therapies. It also has a strong pipeline of promising drugs in development, which could be transformative for the company and its shareholders. Overall, SVB Leerink’s updated rating and lower price target for Recursion Pharmaceuticals reflect the uncertainty surrounding the company’s potential and the challenges it faces in generating revenue.

However, analysts remain hopeful that the company’s long-term prospects remain positive, and that its drug discovery platform will eventually yield results. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Recursion Pharmaceuticals. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Recursion Pharmaceuticals. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Recursion Pharmaceuticals. More…

Key Ratios Snapshot

Some of the financial key ratios for Recursion Pharmaceuticals are shown below. More…

VI Analysis

Analysis of RECURSION PHARMACEUTICALS‘ fundamentals can be made simple with the help of VI app. According to the VI Star Chart, RECURSION PHARMACEUTICALS is classified as ‘cheetah’, which means it has achieved a high revenue or earnings growth, but is considered less stable due to lower profitability. Investors interested in this type of company may be looking for potential growth and are willing to take on some risk associated with it. The VI app also shows that RECURSION PHARMACEUTICALS has an intermediate health score of 6/10 considering its cashflows and debt, indicating that it might be able to pay off debt and fund future operations. Moreover, the app reveals that the company is strong in terms of assets and growth, but weak in terms of dividends and profitability. Thus, investors should consider all of these factors when assessing RECURSION PHARMACEUTICALS’ fundamentals for long-term potential. More…

VI Peers

The company was founded in 2013 by Christopher R. Gibson and Brendan Frey. Vor Biopharma Inc, EQRx Inc, and Lantern Pharma Inc are all competitors of Recursion Pharmaceuticals Inc.

– Vor Biopharma Inc ($NASDAQ:VOR)

Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with serious and life-threatening diseases. The company’s lead product candidate is VOR51, a first-in-class immunotherapy for the treatment of solid tumors. Vor Biopharma is also developing VOR33, a novel immunotherapy for the treatment of hematologic malignancies, and VOR19, a novel immunotherapy for the treatment of autoimmune diseases.

– EQRx Inc ($NASDAQ:EQRX)

EQRx is a biopharmaceutical company that focuses on the development of innovative therapies for patients with serious diseases. The company has a market cap of $2.42 billion and a return on equity of -12.39%. EQRx is headquartered in Cambridge, Massachusetts.

– Lantern Pharma Inc ($NASDAQ:LTRN)

Lantern Pharma Inc has a market cap of 46.57M as of 2022. The company’s return on equity is 16.74%.

Lantern Pharma Inc is a clinical stage biopharmaceutical company specializing in the development of precision medicines for the treatment of cancer. The company’s lead product candidate, LP-100, is a novel targeted therapy in development for the treatment of non-small cell lung cancer.

Summary

Recursion Pharmaceuticals is a biotechnology company focused on using artificial intelligence to discover treatments for rare and genetic diseases. SVB Leerink has recently updated its rating on Recursion Pharmaceuticals from Outperform to Market Perform, with a lower price target of $8. The market sentiment toward the company has been mostly negative, as investors remain cautious about the potential of its technology and the long-term prospects of the company. Despite this, analysts remain optimistic about the long-term potential that Recursion Pharmaceuticals has, and believe that its technology could be a game-changer in the field of rare and genetic diseases.